On June 24, HRSA announced that it had issued new grant award terms to its HRSA-funded health centers to provide insulin and injectable epinephrine at or below the 340B price paid by the health center for the drugs. HRSA...more
6/27/2025
/ Drug Pricing ,
Executive Orders ,
Federal Funding ,
Government Agencies ,
Grants ,
Healthcare Facilities ,
Healthcare Reform ,
HRSA ,
Prescription Drugs ,
Regulatory Requirements ,
Reporting Requirements ,
Section 340B ,
Trump Administration
Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide injection products Wegovy and Ozempic (the “February Declaratory Order”). On March...more
3/21/2025
/ Enforcement Actions ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Popular ,
Prescription Drugs ,
Regulatory Authority ,
Regulatory Requirements